The goal in conducting this study is to determine the current status of the DNA diagnostics industry and to assess its growth potential over a 5-year period from 2008 to 2013.  We are particularly interested in the markets for DNA microarrays, PCR-based assays, fluorescent in situ hybridization, and biochips.

In addition, we are interested in the market for DNA assays for specific clinical applications. For each, we examine the technology, development process, market penetration and the projected market for each diagnostic assay through 2013.

Our key objective is to present a comprehensive analysis of the current market and its future direction. 

DNA-based assays continue to move from research settings into the clinic and as such they represent one of the fastest growing segments of diagnostics.  We are interested in the innovations in microarrays, PCR assays, biochips and other common technologies for DNA detection as they are modified for routine clinical use. 

As nucleic acid testing becomes routine, a number of related issues have come to the fore including government regulation, reimbursement through insurance, patient confidentiality and other legal ramifications.  These developments and their impact on the DNA diagnostics business are also covered in this report.

This study examines the global market for assays used to detect specific nucleic acid sequences in medical and life sciences applications.  While the goal of all DNA-based diagnostic assays is similar, several different technologies can be employed. This report  analyzes each technology in detail and determines major players, current market status and presents forecasts of growth over the next 5 years.  Scientific challenges and advances, including the latest trends, are emphasized. 

We examine government regulations, major collaborations, recent patents and factors affecting the industry worldwide.  In addition, we examine new directions for DNA diagnostic technologies and emerging applications in clinical diagnostics.

This study will be of interest to technology and business professionals in the pharmaceutical, health care, genomics and biotechnology industries. Business development professionals, market analysts, consultants, and investors working in medical biotechnology will also find this report valuable. 

This Report:

• By the end of 2008, the global DNA diagnostics market is expected to be valued at $10.6 billion. The total market is projected to grow at a compound annual growth rate (CAGR) of 13.7% to reach $20.1 billion in 2013.
• PCR-based diagnostic assays should claim the largest share of the market in 2008 and be worth $5.4 billion. The segment will reach $9.5 billion in 2013, for a CAGR of 11.9%.
• The fastest growing segment of the DNA diagnostics market is the LOAC market, which is expected to reach $890 million in 2008 and $2.1 billion in 2013, for a CAGR of 18.7%.

TABLE OF CONTENTS

Chapter- 1: INTRODUCTION

Chapter- 2: SUMMARY

Chapter- 3: OVERVIEW

Chapter- 4: REGULATORY FACTORS

Chapter- 5: MARKET FOR CLINICAL DNA DIAGNOSTICS BY TECHNOLOGY, THROUGH 2013

Chapter- 6: MARKETS BY APPLICATION

Chapter- 7: PATENT ANALYSIS

Chapter- 8: INDUSTRY STRUCTURE

Chapter- 9: COMPANY PROFILES